Neuraxis, Inc. NRXS
i
Market dataready · fetched 2026-11-11T15:22:10.853Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:20:20.592479984Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T15:22:10.418008+00:00
Neuraxis, Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.67 | 140.6% | 17.5% | |||
| 25Δ | 11.78 | 384.6% | 96.0% | 5.91 | 157.4% | 16.5% |
| 30Δ | 10.66 | 361.9% | 79.3% | 6.14 | 174.1% | 15.6% |
| 35Δ | 9.53 | 339.2% | 62.5% | 6.38 | 190.9% | 14.6% |
| 40Δ | 8.40 | 316.5% | 45.8% | 6.62 | 207.6% | 13.6% |
| 45Δ | 7.43 | 295.9% | 31.6% | 6.86 | 224.4% | 12.7% |
| 50Δ | 7.08 | 283.9% | 27.7% | 7.09 | 241.2% | 11.7% |
| 55Δ | 6.72 | 271.8% | 23.8% | 7.33 | 257.9% | 10.8% |
| 60Δ | 6.37 | 259.7% | 19.9% | |||
| 65Δ | 6.02 | 247.6% | 16.0% | |||
| 70Δ | 5.67 | 235.6% | 12.1% | |||
| 75Δ | 5.31 | 223.5% | 8.2% | |||
| 80Δ | 4.90 | 224.9% | 4.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.67
- IV
- 140.6%
- B/E move
- 17.5%
25Δ
- Pseudo strike
- 11.78
- IV
- 384.6%
- B/E move
- 96.0%
- Pseudo strike
- 5.91
- IV
- 157.4%
- B/E move
- 16.5%
30Δ
- Pseudo strike
- 10.66
- IV
- 361.9%
- B/E move
- 79.3%
- Pseudo strike
- 6.14
- IV
- 174.1%
- B/E move
- 15.6%
35Δ
- Pseudo strike
- 9.53
- IV
- 339.2%
- B/E move
- 62.5%
- Pseudo strike
- 6.38
- IV
- 190.9%
- B/E move
- 14.6%
40Δ
- Pseudo strike
- 8.40
- IV
- 316.5%
- B/E move
- 45.8%
- Pseudo strike
- 6.62
- IV
- 207.6%
- B/E move
- 13.6%
45Δ
- Pseudo strike
- 7.43
- IV
- 295.9%
- B/E move
- 31.6%
- Pseudo strike
- 6.86
- IV
- 224.4%
- B/E move
- 12.7%
50Δ
- Pseudo strike
- 7.08
- IV
- 283.9%
- B/E move
- 27.7%
- Pseudo strike
- 7.09
- IV
- 241.2%
- B/E move
- 11.7%
55Δ
- Pseudo strike
- 6.72
- IV
- 271.8%
- B/E move
- 23.8%
- Pseudo strike
- 7.33
- IV
- 257.9%
- B/E move
- 10.8%
60Δ
- Pseudo strike
- 6.37
- IV
- 259.7%
- B/E move
- 19.9%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 6.02
- IV
- 247.6%
- B/E move
- 16.0%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 5.67
- IV
- 235.6%
- B/E move
- 12.1%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 5.31
- IV
- 223.5%
- B/E move
- 8.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 4.90
- IV
- 224.9%
- B/E move
- 4.7%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 101.24% | |
| 92.99% | |
| 112.06% | |
| 100.17% | |
| 95.72% | |
| 105.53% | |
| 109.63% | |
| 91.50% |
Biotechnology
NTLA
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
More →NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
More →NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs.…
More →NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. The company is headquartered in…
More →OABI
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology…
More →OBIO
Description unavailable
More →